Skip to content

Prolactin Receptor and Breast Diseases

Characterization and Implication of Prolactin Receptor Mutants in Human Breast Diseases

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00842465
Acronym
Prolacsein
Enrollment
735
Registered
2009-02-12
Start date
2008-09-30
Completion date
2012-06-30
Last updated
2013-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign Breast Disease, Breast Cancer

Keywords

Breast diseases,, human mutation,, prolactin receptor;, breast cancer

Brief summary

Prolactin is known to play an important role in breast development and differentiation. Thus proliferative breast diseases are good models to unravel PRl / PRLR function in proliferative processes. The aim of this project is to identify and to characterize new mutants of the prolactin receptor gene within cohorts of benign or malign breast diseases with low or high occurrence frequency in human populations

Detailed description

There is currently no known genetic disease linked to prolactin (prl) or its receptor (prlR) in humans. In a previous work, we have identified a new mutation of prolactin receptor that leads to it's constitutive activation and to cell proliferation signalling cascades (i.e. through MAP kinases). This result suggests that PRLR mutants may have a strong physiopathological impact on breast diseases etiology and/or development and/or evolution. Based on this, we will pursue the identification of new PRLR mutants in various breast diseases and continue their in vitro functional characterization and then analyse their in vivo consequences on breast tissue samples collected within these women. 1. In a first time we wish to confirm our previous results on multiple fibroadenomas (MFA). The current cohort will be augmented with 30 to 35 new patients each year. We will confirm our in vitro results in vivo with tumoral and peri-tumoral tissue samples. 2. We then wish to extend this study to other rare breast pathologies (i.e. gigantomastia, phyllodies tumors, giant fibroadenomas) and to more common ones (simple fibroadenomas) to demonstrate a link between simple FA and MFA. 3. in a third time we will try to determinate whether a constitutive activation of PRLR leads to enhanced occurrence of benign / malign transitions.

Interventions

OTHERultrasonography (pelvis and breast), bone mineral density

ultrasonography (pelvis and breast), bone mineral density

BIOLOGICALblood collection for hormonal status analysis

for hormonal status analysis

PROCEDUREbreast Biopsy or surgery

breast Biopsy or surgery

GENETICblood collection

blood collection for prlR gene sequencing

Sponsors

Institut Pasteur
CollaboratorINDUSTRY
Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
FEMALE
Age
10 Years to No maximum
Healthy volunteers
No

Inclusion criteria

: * benign breast diseases * 10 \< age \< 25 for simple FA * 10 \< age \< 50 for other diseases .no hormonal treatment for at least 3 months if patients took cyproterone acetate; 1 month for other ovaries-interfering hormonal treatment, and 1 week for ovaries-non-interfering hormonal treatments. * Signature of the informed consent form (icf) by patients or their legal representative (for patients under age of 18.) * breast cancer : * having a breast cancer with a planned surgery * age \> 55 years * post menopausal with not menopause substitution treatment * signature of the icf * control group : * 18 \< age \< 60 * signature of the icf

Exclusion criteria

: * no signature or no conformity of the icf * no social security

Design outcomes

Primary

MeasureTime frame
Sequencing of PRLRat inclusion

Secondary

MeasureTime frame
Breast MRIat inclusion
Pelvic ultrasonographyat inclusion
Bone mineral density measurementat inclusion
Breast ultrasonographyat inclusion
Histological analysis of tumoral and peri-tumoral tissuesat surgery
Tumor transcriptome analysisat surgery
Hormonal and metabolic evaluationat inclusion

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026